AIMS/HYPOTHESIS: Measurement of plasma apolipoprotein (Apo) B may improve prediction of cardiovascular risk, as it provides a measure of the total number of atherogenic particles. The aim of this population-based study was to compare the association of non-HDL-cholesterol, ApoB and the ApoB:ApoA-I ratio with cardiovascular mortality in people with type 2 diabetes. SUBJECTS AND METHODS: We assessed the association of lipids, lipoprotein lipids and apolipoproteins with 11-year mortality from cardiovascular disease in the population-based cohort of the Casale Monferrato Study (1,565 people with diabetes; median age 68.9 years), and determined the effect of age (< or =70 and >70 years) on these relationships. RESULTS: On the basis of 341 deaths from cardiovascular disease in 10,809 person-years of observation, there was a decreasing trend in risk adjusted for multiple factors across quartiles of total cholesterol, and LDL- and non-HDL-cholesterol in people aged >70 years, but no trend in those aged < or =70 years. Age did not affect the protective effect of HDL-cholesterol. ApoB and ApoB:ApoA-I were associated with outcome in people in both age groups independently of non-HDL-cholesterol. After adjustment for multiple factors, including non-HDL-cholesterol, the hazard ratios for ApoB:ApoA-I in the upper vs lower quartile were 2.98 (95% CI 1.15-7.75; p for trend=0.009) for people aged < or =70 years and 1.94 (95% CI 1.20-3.13; p for trend=0.003) for those aged >70 years. CONCLUSIONS/ INTERPRETATION: In this cohort of Mediterranean subjects with diabetes, ApoB and the ApoB:ApoA-I ratio were associated with cardiovascular disease mortality independently of non-HDL-cholesterol. Our findings support the recommendation that ApoB and ApoA-I should be measured routinely in all people with diabetes, particularly in the elderly.
AIMS/HYPOTHESIS: Measurement of plasma apolipoprotein (Apo) B may improve prediction of cardiovascular risk, as it provides a measure of the total number of atherogenic particles. The aim of this population-based study was to compare the association of non-HDL-cholesterol, ApoB and the ApoB:ApoA-I ratio with cardiovascular mortality in people with type 2 diabetes. SUBJECTS AND METHODS: We assessed the association of lipids, lipoprotein lipids and apolipoproteins with 11-year mortality from cardiovascular disease in the population-based cohort of the Casale Monferrato Study (1,565 people with diabetes; median age 68.9 years), and determined the effect of age (< or =70 and >70 years) on these relationships. RESULTS: On the basis of 341 deaths from cardiovascular disease in 10,809 person-years of observation, there was a decreasing trend in risk adjusted for multiple factors across quartiles of total cholesterol, and LDL- and non-HDL-cholesterol in people aged >70 years, but no trend in those aged < or =70 years. Age did not affect the protective effect of HDL-cholesterol. ApoB and ApoB:ApoA-I were associated with outcome in people in both age groups independently of non-HDL-cholesterol. After adjustment for multiple factors, including non-HDL-cholesterol, the hazard ratios for ApoB:ApoA-I in the upper vs lower quartile were 2.98 (95% CI 1.15-7.75; p for trend=0.009) for people aged < or =70 years and 1.94 (95% CI 1.20-3.13; p for trend=0.003) for those aged >70 years. CONCLUSIONS/ INTERPRETATION: In this cohort of Mediterranean subjects with diabetes, ApoB and the ApoB:ApoA-I ratio were associated with cardiovascular disease mortality independently of non-HDL-cholesterol. Our findings support the recommendation that ApoB and ApoA-I should be measured routinely in all people with diabetes, particularly in the elderly.
Authors: Rui Jiang; Matthias B Schulze; Tricia Li; Nader Rifai; Meir J Stampfer; Eric B Rimm; Frank B Hu Journal: Diabetes Care Date: 2004-08 Impact factor: 19.112
Authors: Allan D Sniderman; Annie C St-Pierre; Bernard Cantin; Gilles R Dagenais; Jean-Pierre Després; Benoît Lamarche Journal: Am J Cardiol Date: 2003-05-15 Impact factor: 2.778
Authors: J David Curb; Robert D Abbott; Beatriz L Rodriguez; Kamal H Masaki; Randi Chen; Jordan S Popper; Helen Petrovitch; G Webster Ross; Irwin J Schatz; Gina C Belleau; Katsuhiko Yano Journal: Am J Epidemiol Date: 2004-07-15 Impact factor: 4.897
Authors: Seth S Martin; Atif N Qasim; Megan Wolfe; Caitlin St Clair; Stanley Schwartz; Nayyar Iqbal; Mark Schutta; Roshanak Bagheri; Nehal N Mehta; Daniel J Rader; Muredach P Reilly Journal: Am J Cardiol Date: 2011-02-01 Impact factor: 2.778
Authors: Nehal N Mehta; Parasuram Krishnamoorthy; Seth S Martin; Caitlin St Clair; Stanley Schwartz; Nayyar Iqbal; Seth Braunstein; Mark Schutta; Daniel J Rader; Muredach P Reilly Journal: Am J Cardiol Date: 2011-02-01 Impact factor: 2.778
Authors: Brian T Steffen; Weihua Guan; Alan T Remaley; Pathmaja Paramsothy; Susan R Heckbert; Robyn L McClelland; Philip Greenland; Erin D Michos; Michael Y Tsai Journal: Arterioscler Thromb Vasc Biol Date: 2014-12-04 Impact factor: 8.311
Authors: Chaoyang Li; Earl S Ford; James Tsai; Guixiang Zhao; Lina S Balluz; Samuel S Gidding Journal: Cardiovasc Diabetol Date: 2011-05-23 Impact factor: 9.951